Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of bone metastases in patients with castration-resistant prostate cancer.
Cathomas R, Bajory Z, Bouzid M, El Ghoneimy A, Gillessen S, Goncalves F, Kacso G, Kramer G, Milecki P, Pacik D, Tantawy W, Lesniewski-Kmak K. Cathomas R, et al. Among authors: gillessen s. Urol Int. 2014;92(4):377-86. doi: 10.1159/000358258. Epub 2014 Apr 30. Urol Int. 2014. PMID: 24802278 Free article. Review.
Primary manifestation of small lymphocytic lymphoma in the prostate.
Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen S, Cathomas R. Fehr M, et al. Among authors: gillessen s. Onkologie. 2009 Oct;32(10):586-8. doi: 10.1159/000232584. Epub 2009 Sep 11. Onkologie. 2009. PMID: 19816076 Review.
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK). von Moos R, et al. Among authors: gillessen s. Ann Oncol. 2012 Feb;23(2):531-6. doi: 10.1093/annonc/mdr126. Epub 2011 Apr 28. Ann Oncol. 2012. PMID: 21527587 Free article. Clinical Trial.
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK. Cathomas R, et al. Among authors: gillessen s. Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12. Clin Cancer Res. 2012. PMID: 22977195 Clinical Trial.
300 results